Earnings Highlights
EPS Actual
-0.10
EPS Estimate
-0.10
Revenue Actual
Revenue Estimate
***
Every investor deserves access to professional-grade tools and analysis. Compass Therapeutics Inc. (CMPX) reported a first-quarter 2026 loss per share of -$0.10, marginally ahead of the consensus estimate of -$0.1001 and representing a positive surprise of 0.1. The pre-revenue biotech company recorded no revenue during the quarter, as expected. Shares rose 2.12% following the announcement, reflecting investor optimism around the company’s clinical-stage pipeline and disciplined cost management.